Genitourinary Toxicity After High-Dose-Rate (HDR) Brachytherapy Combined With Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer: An Analysis to Determine the Correlation Between Dose-Volume Histogram Parameters in HDR Brachytherapy and Severity of Toxicity

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 23-28

  Ishiyama, Hiromichi ^a   Kitano, Masashi ^a   Satoh, Takefumi ^a   Kotani, Shouko ^a   Uemae, Mineko ^b   Matsumoto, Kazumasa ^a   Okusa, Hiroshi ^a   Tabata, Ken ichi ^a   Baba, Shiro ^a   Hayakawa, Kazushige ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

192 Iridium; Dose volume histogram; High dose rate brachytherapy; Prostate cancer; Urinary toxicity

Indexed keywords

192-IRIDIUM; DOSE-VOLUME HISTOGRAM; HIGH-DOSE-RATE BRACHYTHERAPY; PROSTATE CANCER; URINARY TOXICITY;

IRIDIUM; RADIOTHERAPY;

TOXICITY;

FLUTAMIDE; GONADORELIN AGONIST; IRIDIUM 192;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CONTROLLED STUDY; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; HEMATURIA; HISTOGRAM; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT PLANNING; URETHRA STRICTURE; URETHROTOMY; URINE RETENTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; FLUTAMIDE; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RECTUM; REGRESSION ANALYSIS; RELATIVE BIOLOGICAL EFFECTIVENESS; TUMOR BURDEN; URETHRA; UROGENITAL SYSTEM;

EID: 68649099970     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.11.006     Document Type: Article

References (27)

1. Pollack A., Zagars G.K., Starkshall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
2. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
3. Hanks G.E., Schultheiss T.E., Hanlon A.L., et al. Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study. Int J Radiat Oncol Biol Phys 37 (1997) 543-550
4. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
5. Egawa S., Shimura S., Irie A., et al. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 31 (2001) 541-547
6. Satoh T., Kitano M., Fujita T., et al. High-dose rate iridium-192 brachytherapy boost to external beam radiation therapy for prostate cancer in Japanese men. Jpn J Endourol ESWL 18 (2005) 273-277
7. Akimoto T., Ito K., Saitoh J., et al. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Int J Radiat Oncol Biol Phys 63 (2005) 463-471
8. Akimoto T., Katoh H., Noda S., et al. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Int J Radiat Oncol Biol Phys 63 (2005) 472-478
9. Cassio A., Pellizzon A., Salvajoli J.V., et al. Late urinary toxicity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol 171 (2004) 1105-1108
10. Tharp M., Bennett R., Burns J., et al. Prostate high dose rate brachytherapy in a free-standing cancer center setting. Am J Clin Oncol 30 (2007) 520-525
11. Chen Y., Chuand C., Hsieh M., et al. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: An experience in Taiwan. Urology 70 (2007) 101-105
12. Duchesne G.M., Williams S.G., Das R., et al. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. Radiother Oncol 84 (2007) 128-134
13. Hoskin P.J., Motohashi K., Bownes P., et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomized phase three trial. Radiother Oncol 84 (2007) 114-120
14. Chiand P.H., Fang F.M., Jong W.C., et al. High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation. Int J Urol 11 (2004) 152-158
15. Phan T.P., Syed A.M.N., Puthawala A., et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 177 (2007) 123-127
16. Vargas C.E., Martinez A.A., Boike T.P., et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 66 (2006) 416-423
17. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61 (2005) 1306-1316
18. Pinkawa M., Fischedick K., Treusacher P., et al. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer-A phase II study. Radiother Oncol 78 (2006) 41-46
19. Galalae R.M., Martinez A., Nuernberg N., et al. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer: Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?. Strahlenther Onkol 182 (2006) 135-141
20. Aström L., Pedersen D., Mercke C., et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localized prostate cancer. Radiother Oncol 74 (2005) 157-161
21. Jo Y., Hiratsuka J., Fujii T., et al. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer. Urology 64 (2004) 556-560
22. Stevens M.J., Stricker P.D., Saalfeld J., et al. Treatment of localized prostate cancer using a combination of high dose rate iridium-192 brachytherapy and external beam irradiation: Initial Australian experience. Australas Radiol 47 (2003) 152-160
23. Yoshioka Y., Nose T., Yoshida K., et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56 (2003) 213-220
24. Martinez A. Gonzalez, J, Spencer W. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169 (2003) 974-980
25. Duchesne G., Das R., Toye W., et al. Dose distribution and toxicity after high dose rate brachytherapy for prostate cancer: Influence of V150 and V200 parameters. Australas Radiol 46 (2002) 384-389
26. Deger S., Boehmer D., Roigas J., et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 47 (2005) 441-448
27. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the RTOG and EORTC. Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346